DiagnaMed Opens Enrollment For Healthcare Provider Network For Brain Health Platform
DiagnaMed Holdings (CSE: DMED) is moving forward with the commercialization of CERVAI, its brain health AI platform.
Read more
DiagnaMed Holdings
DiagnaMed Expects Brain Health AI Platform To Be Commercialized In Q4 2023
DiagnaMed Holdings (CSE: DMED) is anticipating to begin the commercialization stage of its flagship CERVAI brain health AI platform in the fourth quarter of 2023.
Read more
DiagnaMed Anticipates CERVAI Commercial Launch In Q4 2023
DiagnaMed Holdings (CSE: DMED) is expected to begin the deployment of its brain age estimation tool known as CERVAI to third party sites in the fourth quarter of 2023.
Read more
DiagnaMed Launches Dr. GenAI, A Generative AI Medical Chatbot
DiagnaMed Holdings (CSE: DMED) has launched its third generative AI product to the marketplace.
Read more
DiagnaMed Launches Division For Generative AI Healthcare Applications
FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings. A new division has been established by DiagnaMed Holdings (CSE: DMED) to
Read more
DiagnaMed Unveils First Commercial AI Product For Healthcare Industry, FormGPT
DiagnaMed Holdings (CSE: DMED) has launched its first commercial product under its initiative to bring artificial intelligence to the healthcare industry. The initiative is currently focused on using AI to improve patient outcomes, operational workflow, and efficiency within the industry.
Read more
DiagnaMed Brings AI To Brain Health — With Fabio Chianelli And Dr. John Kounios
Joining us today on the Daily Dive is that of DiagnaMed Holdings (CSE: DMED) Chairman Fabio Chianelli, and Dr. John
Read more
DiagnaMed Licenses Brain Health Tech From University Of Miami For AI Platform
DiagnaMed Holdings (CSE: DMED) is moving to enhance its brain health artificial intelligence platform known as CERVAI. The company has
Read more
DiagnaMed Focuses On Brain Health AI Platform Development
DiagnaMed Holdings (CSE: DMED) appears to be going all in on artificial intelligence. The drug development firm this morning revealed
Read more
DiagnaMed Looks To Obtain Approval For Brain Age Clinical Tool In Q4
DiagnaMed Holdings (CSE: DMED) is moving towards obtaining regulatory approval for its Brain Age clinical solution by the end of
Read more